31.2 C
New York
Thursday, July 3, 2025

Tag: genetics

Rubicon Organics Launches 1964 Supply Co.™ All-in-One FSE Resin Vapes in Canada

VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics”, “Rubicon”, or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling organic certified, premium and super-premium cannabis products, is proud to announce the launch of its new 1964 Supply Co.™ (“1964”) All-in-One (“AIO”) Full Spectrum Extract (“FSE”) Resin Vapes into the Canadian market.

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

Highest THCa Flower July 2025: New Hemp Hop Strains Hit the Market

Hemp Hop launches the Best THCa flower strains of July 2025 with London Jealousy and Gravel Pit, known for premium quality and high THCa content.

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. (TEM) Investors with Substantial Losses Have Opportunity to Lead Class Action...

SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, all dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.

Baylor Genetics’ Chairman and CEO Kengo Takishima Named One of Houston Business Journal’s 2025 Most Admired CEOs

Award is one of Houston’s most inspiring celebrations of leadership, where CEOs and visionaries are at the helm of the city’s most successful and impactful organizations
Award is one of Houston’s most inspiring celebrations of leadership, where CEOs and visionaries are at the helm of the city’s most successful and impactful organizations

42 Fast Buds Evolves: New Logo, Same Rebel Spirit

LOS ANGELES, June 30, 2025 /PRNewswire/ -- For over a decade, the iconic 42 Fast Buds logo-a bold cannabis leaf paired with the number...

AI Is Quietly Reinventing Healthcare–And Real Deployments Are Now Underway

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul...

MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY

In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will...

4Front Ventures Provides Update on Receivership Proceedings and Board Resignations

PHOENIX, June 26, 2025 /PRNewswire/ - 4Front Ventures Corp. ("4Front" or the "Company") (CSE: FFNT) (OTC: FFNTF), a vertically integrated cannabis operator, provides an update...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform...

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today...

26 ZAZA THCA Flower Strains Unleashed: The Hemp Doctor’s Largest Drop Yet

The Hemp Doctor drops 26 potent indoor-grown ZAZA THCA strains with up to 35% THCA—the largest introduction of organically grown strains to date.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGenetics